Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours Β· Estimated delivery Sep 24 - Sep 29
Rare but serious risks include pancreatitis, gallbladder disease, and thyroid tumors (seen in animal studies, not confirmed in humans but flagged by the FDA)
In both studies, the primary efficacy parameters were mean percent change in body weight and the percentage of patients achieving 5% weight reduction from baseline to Week 72 (see Table 2)
SMOOTHIES 10.2.2.3
Name of the approval committee: The Ethics Committee of the First Affiliated Hospital of Jinan University
US$ 21.77
US$ 28.53
US$ 22.47
